Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas
Clinical trial NCT02900716 · COMPLETED
Trial details
- NCT number
- NCT02900716
- Sponsor
- Zhejiang DTRM Biopharma
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-09-01
- Primary completion
- 2020-11-23
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.